kahuna

Cinryze Approved: A Significant Catalyst for Viropharma, Lev Pharmaceuticals

You didn't mention an important factor; that is CSL Behring has it's version of Cinryze (C1INH) in the FDA's pipeline and has an expectation of approval (most likely for the acute indication) early next year.

Neither company actually developed this medicine; they merely tweaked a drug (to FDA standards) that has been available in Europe for years. Because of this, the FDA will likely allow these two companies to compete in the marketplace. The orphan drug statuses will likely have little meaning as physicians could use each for acute or prophylaxis as desired.